US OptionsDetailed Quotes
ITOS250117P9000
- 1.25
- -0.40-24.24%
15min DelayClose Jan 17 16:00 ET
1.30High1.25Low
1.30Open1.65Pre Close4 Volume6.48K Open Interest9.00Strike Price515.00Turnover0.00%IV3.13%PremiumJan 17, 2025Expiry Date1.00Intrinsic Value100Multiplier-3DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma6.40Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ITeos Therapeutics Stock Discussion
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
Thursday, 12th December at 8:55 am
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS of 7.7 months for all evaluable patients across the cohorts
- Recommended Phase 2 dose (RP2D) of inupadenant 80mg + carboplatin/pemetrexed demonstrat...
$ITeos Therapeutics (ITOS.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Pearson (PSO.US)$
$UnitedHealth (UNH.US)$
$Option Care Health (OPCH.US)$
$Procter & Gamble (PG.US)$
$Montrose Environmental (MEG.US)$
$Nurix Therapeutics (NRIX.US)$
$Datadog (DDOG.US)$
$Pearson (PSO.US)$
$Procter & Gamble (PG.US)$
$Option Care Health (OPCH.US)$
$UnitedHealth (UNH.US)$
No comment yet